Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470024 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
A Phase 1 study of Cancer of the Head and Neck, sponsored by Providence Health & Services.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04470024: Recruiting Phase 1 study of Cancer of the Head and Neck, sponsored by Providence Health & Services.
NCT04470024 is a Phase 1 study of Cancer of the Head and Neck that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 56 participants, above the 41-participant average among 3 other Cancer of the Head and Neck trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04470024, a Phase 1 study of Cancer of the Head and Neck, is actively recruiting participants, sponsored by Providence Health & Services.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Primary Outcome
frequency, duration, and severity of adverse events
Conditions Studied
Interventions
- DRUG INCAGN01876
- DRUG INCMGA00012
- BIOLOGICAL DPV-001
Study Locations (1)
Oregon
- Portland Providence Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT04470024 shows while recruiting
NCT04470024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, above the 41-participant average among 3 other Cancer of the Head and Neck trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Cancer of the Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which INCAGN01876 is the first listed.
NCT04470024 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04470024 about?
NCT04470024 is a clinical study titled "Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC". This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
What is the current status of trial NCT04470024?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-08-05. Estimated completion is 2027-12-31.
What conditions does trial NCT04470024 study?
This clinical trial studies the following conditions: Cancer of the Head and Neck.
What interventions are being tested in trial NCT04470024?
The interventions under investigation include: INCAGN01876 (DRUG), INCMGA00012 (DRUG), DPV-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04470024?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04470024 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI